Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Miaomiao Ge
Observed name:
M. Ge
Institution:
Boehringer Ingelheim (United States)
Observed institutions:
University of Connecticut,
Innsbruck Medical University,
Pfizer (United States),
Universität Innsbruck,
Boehringer Ingelheim (United States)
ORCID:
0009-0005-5842-2913
Observed ORCID:
0009-0005-5842-2913
OpenAlex ID:
A5014862768
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
2023
·
Madeline Pe
, Ahu Alanya
, et al.
·
The Lancet Oncology
·
78
PDF
Hydroponic Screening of Willows (SalixL.) for Lead Tolerance and Accumulation
2010
·
Olena P. Zhivotovsky
, Julia A. Kuzovkina
, et al.
·
International Journal of Phytoremediation
·
67
Covariate-Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences
2011
·
Miaomiao Ge
, L. Kathryn Durham
, et al.
·
Drug Information Journal
·
41
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
2021
·
Hartmut Döhner
, Argiris Symeonidis
, et al.
·
HemaSphere
·
35
Reducing Adverse Self-Medication Behaviors in Older Adults with Hypertension: Results of an e-health Clinical Efficacy Trial
2010
·
Patricia J. Neafsey
, Cyr E. M’lan
, et al.
·
Ageing International
·
34
PDF
Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli
2010
·
L. K. Durham
, M. Ge
, et al.
·
European Journal of Clinical Microbiology & Infectious Diseases
·
33
Bayesian inference of the fully specified subdistribution model for survival data with competing risks
2012
·
Miaomiao Ge
, Ming-Hui Chen
·
Lifetime Data Analysis
·
15
Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.
2020
·
Melissa Lynne Johnson
, Manish R. Patel
, et al.
·
Journal of Clinical Oncology
·
14
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
2015
·
Daniel J. DeAngelo
, Mikkael A. Sekeres
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
10
A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development
2023
·
Pingye Zhang
, Xiaoyun (Nicole) Li
, et al.
·
Contemporary Clinical Trials
·
7
Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors
2018
·
M.L. Johnson
, M.R. Patel
, et al.
·
Annals of Oncology
·
4
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
2024
·
Manish R. Patel
, Melissa Johnson
, et al.
·
Cancer Immunology Immunotherapy
·
3
PDF
Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.
2018
·
Melissa Lynne Johnson
, Manish R. Patel
, et al.
·
Journal of Clinical Oncology
·
3
An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.
2020
·
Yoon-Koo Kang
, Kensei Yamaguchi
, et al.
·
Journal of Clinical Oncology
·
2
Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
2019
·
Johanna Bendell
, Susanna V Ulahannan
, et al.
·
Molecular Cancer Therapeutics
·
2
A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors
2018
·
Melissa Johnson
, Manish Patel
, et al.
·
Annals of Oncology
·
1
Bayesian methodology for survival data with competing risks
2011
·
Miaomiao Ge
·
OpenCommons - UConn (University of Connecticut)
Show more works
View as search
Works count:
17
Citation count:
378
H-index:
9
I10-index:
9
Year
Topic
Type